GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31

CytoMed Therapeutics Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026

$0.85−0.03 (-3.17%)

Close on Oct 19, 2026

CytoMed Therapeutics Ltd income statement

AnnualQuarterlyTTM

SGD USD

Millions of SGD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	0.32	0.07	–	–	–	–
Research & Development	2.22	1.91	1.59	1.52	1.09	1.04
Advertising Expenses	0.05	0.02	0.03	–	0.00	0.01
Interest Expense	0.02	0.02	0.05	0.13	0.12	0.11
Income from Equity Investments	-0.01	0.01	-0.03	-0.03	0.00	–
Pretax Income	-4.00	-2.52	-4.13	-3.13	-2.05	-1.94
Income Tax Expense	–	–	0.00	0.00	–	–
Net Income incl. Noncontrolling Interests	-4.00	-2.52	-4.13	-3.13	-2.05	-1.94
Minority Interest in Earnings	–	-0.01	0.00	0.00	0.00	0.00
Net Income	-3.98	-2.52	-4.13	-3.13	-2.05	-1.94
EPS (Basic)(per share)	-0.34	-0.22	-0.39	-0.40	-0.30	–
EPS (Diluted)(per share)	-0.34	-0.22	-0.39	-0.40	-0.30	-0.33
Shares Outstanding (Basic, Weighted)(shares)	12	12	11	7.92	6.93	–
Shares Outstanding (Diluted, Weighted)(shares)	12	12	11	7.92	6.93	5.90

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: -1227.1%
Return on equity, FY2025: -51.3%

Financial strength

Current ratio: 5.17
Debt to equity: 0.06
Debt to assets: 5.1%
Cash to current liabilities: 295.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.